Abstract: The invention provides a method of delivering, by intermittent inhalation, 200 ppm to 320 ppm gNO for 10 to 45 minutes 2 to 5 times per day to provide a therapeutic amount of gaseous nitric oxide (gNO) wherein the therapeutic amount is a nitric oxide-load (NO load) of 300 ppm-hrs to 900 ppm-hrs of gNO per day over a period of at least 14 days to a patient in need thereof, wherein the patient has a condition associated with a pathogenic microorganism, wherein the intermittent inhalation comprises inhalation of the gNO for a first time period, followed by inhalation of a gas essentially devoid of gNO for a second time period.

Abstract: Provided herein are compounds that inhibit glycogen synthase kinase-3 (GSK3) giving them antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (I) and (II), for use as antiviral agents in the treatment or prevention of viral infection. Methods for using the GSK3 inhibitor compounds in the treatment or prophylaxis of a viral infection are provided. In particular, the viral infection may be selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 SARS-CoV-1) infection; SARS coronavirus-2 (SARS-CoV-2) infection; and Middle East Respiratory Syndrome (MFRS) coronavirus (MERS-CoV) infection. More specifically, the viral infection may be a human coronavirus 229E (HCoV-229E) infection.

Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.

Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.

Abstract: The invention provides a method of treating a subject having a medical condition associated with a pathogenic microorganism, the method comprising administering to said subject a potentiating effective amount of nitric oxide; and administering to said subject a therapeutically effective amount of an antimicrobial agent, wherein said antimicrobial agent is other than said nitric oxide.

Abstract: The invention provides a method of treating a subject having a medical condition associated with a pathogenic microorganism, the method comprising administering to said subject a potentiating effective amount of nitric oxide; and administering to said subject a therapeutically effective amount of an antimicrobial agent, wherein said antimicrobial agent is other than said nitric oxide.

Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.

Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.

Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

Abstract: In some embodiments, the present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air, compared an infant that is not subjected to the repeated administration of nitric oxide; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5, compared an infant that is not subjected to the repeated administration of nitric oxide; c) reduce the length of time of hospitalization required to be discharged, compared an infant that is not subjected to the repeated adminis

Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

Abstract: In some embodiments, the present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air, compared an infant that is not subjected to the repeated administration of nitric oxide; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5, compared an infant that is not subjected to the repeated administration of nitric oxide; c) reduce the length of time of hospitalization required to be discharged, compared an infant that is not subjected to the repeated adminis

Abstract: A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Abstract: In one embodiment, the present invention provides a system to deliver at least one therapeutic gas to a spontaneously breathing patient, wherein the rate of delivery of the at least one therapeutic gas exceeds the patient's inspiratory flow rate, and the amount of the at least one therapeutic gas that is wasted is minimized or eliminated.

Abstract: The present invention provides a method for treating bronchiolitis in an infant in need thereof, wherein the method comprises repeatedly administering to the infant a gas mixture comprising nitric oxide at a concentration from about 144 to about 176 ppm for a first period of time, followed by a gas mixture containing no nitric oxide for a second period of time, wherein the administration is repeated for a time sufficient to: a) reduce the length of time of hospitalization required to achieve oxygen saturation greater than or equal to 92% in room air; b) reduce the length of time of hospitalization required to achieve a clinical score of less than or equal to 5; c) reduce the length of time of hospitalization required to be discharged; or d) any combination thereof, as compared to an infant that is not subjected to the repeated administration of nitric oxide.

Abstract: A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.